StockNews.AI
AZN
StockNews.AI
168 days

2025 Endothelin Receptor Antagonist Pipeline Insights for 10+ Companies and 15+ Pipeline Drugs, Including Zibotentan (AstraZeneca), SC0062 (Biocity Biopharmaceutics), and GMA301 (Gmax Biopharm)

1. AstraZeneca's zibotentan is in Phase III for chronic kidney disease. 2. Zibotentan may slow tumor growth in cancer patients. 3. Over 10 companies are developing endothelin receptor antagonists. 4. Pipeline includes drugs at various development stages. 5. Report highlights industry collaborations and emerging drug activities.

8m saved
Insight
Article

FAQ

Why Bullish?

The advancement of zibotentan positions AZN strongly against competitors in critical therapy areas.

How important is it?

The focus on zibotentan and its potential in oncology and kidney diseases boosts AZN's growth prospects significantly.

Why Long Term?

Successful Phase III results for zibotentan could lead to significant market penetration and revenue growth over time.

Related Companies

BMYMRKPFE
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Endothelin Receptor Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Report HighlightsCompanies and academics are working to assess challenges and seek opportunities that could influence Endothelin Receptor Antagonist R&D. The therapies under development are focused on novel approaches to treat/improve Endothelin Receptor Antagonist.Endothelin Receptor Antagonist Emerging Drugs ChaptersThis segment of the Endothelin Receptor Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Endothelin Receptor Antagonist Emerging Drugs Zibotentan: AstraZeneca Zibotentan is a novel once daily tablet and works by blocking the endothelin pathway. As prostate cancer advances, this pathway becomes uncontrolled, which then drives the spread of cancer growth. By blocking the endothelin receptor in this pathway, zibotentan can slow tumour growth and the spread of cancer cells. Zibotentan is under development for the treatment of diabetic nephropathy, chronic kidney disease (CKD), cirrhosis with features of portal hypertension and microvascular angina. The drug candidate is administered orally in the form of tablet and capsule. It was also under development for intermittent claudication in peripheral artery disease, patients with non-metastatic castrate resistant prostate cancer, epithelial ovarian cancer, fallopian tube cancer, primary serous peritoneal cancer and non-small cell lung cancer. Currently it is being investigated in Phase III stage of development for the treatment of patients with Chronic Kidney Disease. SC0062: Biocity Biopharmaceutics SC0062 is an ETA highly selective receptor small molecule antagonist developed for chronic kidney disease, dedicated to improving the long-term drug safety of patients with chronic diseases. Preclinical studies have shown that SC0062 has good activity and can effectively improve the pathological scores of acute kidney injury and chronic kidney disease models. In the completed clinical phase I study, SC0062 showed good safety, tolerability and pharmacokinetic characteristics, and no side effects such as water and sodium retention were found, and it is expected to become a potential "Best-in-Class" drug. Currently the drug is in Phase II stage of its development for the treatment of for Diabetic kidney disease and IgA Nephropathy. GMA301: Gmax Biopharm GMA301 is a humanized monoclonal antibody against endothelin receptor A, may become the first long-lasting PAH drug with better efficacy and less adverse effects. Endothelin receptor A/endothelin-1 axis is associated with pulmonary artery hypertension (PAH) and has been targeted for the treatment of PAH. Orphan drug designation has been granted by FDA. Currently the drug is in Phase I stage of clinical trial evaluation for the treatment of Pulmonary Arterial Hypertension.Endothelin Receptor Antagonist: Therapeutic AssessmentThis segment of the report provides insights about the different Endothelin Receptor Antagonist drugs segregated based on following parameters that define the scope of the report, such as:Major PlayersThere are approx. 10+ key companies which are developing the therapies for Endothelin Receptor Antagonist. The companies which have their Endothelin Receptor Antagonist drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca. AstrazenecaBiocity BiopharmaceuticsGmax BiopharmENB TherapeuticsAlchemedicineLassogen Phases The report covers around 15+ products under different phases of clinical development, like: Late stage products (Phase III)Mid-stage products (Phase II)Early-stage product (Phase I) along with the details of: Pre-clinical and Discovery stage candidatesDiscontinued & Inactive candidates Route of AdministrationProducts have been categorized under various ROAs, such as: Intra-articularIntraocularIntrathecalIntravenousOralParenteralSubcutaneousTopicalTransdermal Molecule Type Products have been categorized under various Molecule types, such as: OligonucleotidePeptideSmall molecule Product TypeDrugs have been categorized under various product types like Mono, Combination and Mono/Combination.Pipeline ActivitiesThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endothelin Receptor Antagonist therapeutic drugs key players involved in developing key drugs.Development ActivitiesThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endothelin Receptor Antagonist drugs. Key Questions Answered How many companies are developing Endothelin Receptor Antagonist drugs?How many Endothelin Receptor Antagonist drugs are developed by each company?How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endothelin Receptor Antagonist?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Endothelin Receptor Antagonist therapeutics?What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?What are the clinical studies going on for Endothelin Receptor Antagonist and their status?What are the key designations that have been granted to the emerging drugs? Key Products ZibotentanSC0062GMA301GMA131ENB-003ENB-004ETA antagonistLassotides For more information about this clinical trials report visit https://www.researchandmarkets.com/r/z4i358 About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News